- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07483450
Een onderzoek naar de werkzaamheid, veiligheid, farmacokinetiek en farmacodynamiek van Ocrelizumab bij deelnemers met relapsing multiple sclerose en primair progressieve multiple sclerose
Een multicenter, open-label, single-arm onderzoek naar de effectiviteit, veiligheid, farmacokinetiek en farmacodynamiek van Ocrelizumab bij Chinese patiënten met recidiverende multiple sclerose en primair progressieve multiple sclerose
The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 4
Contacten en locaties
Studie Locaties
-
-
-
Beijing, China, 100034
- Peking University First Hospital
-
Beijing, China, 100032
- Peking Union Medical College Hospital
-
Beijing, China, 100730
- Beijing Hospital of Ministry of Health
-
Changsha, China, 410008
- Xiangya Hospital Central South University
-
Chengdu, China, 610041
- West China Hospital of Sichuan University
-
Chongqing, China, 400016
- The First Affiliated Hospital, Chongqing Medical University
-
Guangzhou, China, 510080
- The First Affiliated Hospital of Sun Yat-sen University
-
Guangzhou, China, 510630
- The Third Affiliated Hospital of Sun Yat-Sen University
-
Hangzhou, China, 310003
- The First Affiliated Hospital of College of Medicine, Zhejiang University
-
Hohhot, China, 010011
- Inner Mongolia Autonomous Region People's Hospital
-
Lanzhou, China, 730030
- Lanzhou University Second Hospital
-
Shenyang, China, DUMMY_VALUE
- The First Hospital of China Medical University
-
Shijiazhuang, China, 050000
- The Second Hospital of Hebei Medical University
-
Taiyuan, China, 030000
- 1st Affiliated Hospital of Shanxi Medical University
-
Wuhan, China, 430030
- Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
-
Ürümqi, China, 830000
- Xinjiang People Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330209
- The First Affiliated Hospital of Nanchang University
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Diagnosis of RMS/PPMS in accordance with the revised 2017 McDonald Criteria
- EDSS score from 0-5.5 (RMS) or 3.0-6.5 (PPMS), inclusive, at screening and baseline
- Documented MRI of brain with abnormalities consistent with MS before screening
Exclusion Criteria:
- Diagnosis of PPMS or non-active secondary progressive multiple sclerosis (SPMS) (only for RMS cohort)
- History of relapsing remitting multiple sclerosis (RRMS) or SPMS at screening (only for PPMS cohort)
- Disease duration of more than 10 years in participants with an EDSS ≤ 2.0 at screening (only for RMS cohort)
- History of confirmed or suspected progressive multifocal leukoencephalopathy (PML)
- Inability to complete an MRI scan or contraindication to Gd administration
- Contraindications to mandatory pre-medications (i.e., corticosteroids and antihistamines)
- Known presence of other neurologic disorders if they could interfere with the diagnosis of MS or assessments of efficacy and/or safety during the study
- Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
- Known history of human immunodeficiency virus (HIV) infection
- Lack of peripheral venous access
- Previous treatment with B-cell targeted therapies (i.e., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab), unless the last infusion was at least 6 months prior to screening
- Positive screening tests for hepatitis B virus (HBV) and/or hepatitis C virus (HCV)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: RMS Cohort
Participants with RMS will receive ocrelizumab, 300 milligrams (mg), intravenous (IV) infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, for all subsequent cycles every 24 weeks (Q24W) (1 Cycle=24 weeks). |
Ocrelizumab will be administered as per the schedule specified in the respective arms.
Andere namen:
|
|
Experimenteel: PPMS Cohort
Participants with PPMS will receive ocrelizumab, 300 mg, IV infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, at Week 24 (1 Cycle=24 weeks). |
Ocrelizumab will be administered as per the schedule specified in the respective arms.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
RMS Cohort: Jaarlijks protocol-gedefinieerde recidiefpercentage
Tijdsspanne: Tot ongeveer 1,6 jaar
|
Tot ongeveer 1,6 jaar
|
|
PPMS Cohort: B-celniveaus in Bloed
Tijdsspanne: Tot week 48
|
Tot week 48
|
|
PPMS Cohort: Percentage van deelnemers die cluster van differentiatie 19 (CD19+) B-cel niveaus van <10 cellen/microliter (μL) bereiken op week 48
Tijdsspanne: In week 48
|
In week 48
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
RMS Cohort: Percentage van deelnemers die geen bewijs hebben van ziekteactiviteit (NEDA3) gedurende een periode van 48 weken
Tijdsspanne: Tot week 48
|
Tot week 48
|
|
|
RMS Cohort: Percentage van deelnemers zonder terugval na 48 weken
Tijdsspanne: Tot week 48
|
Tot week 48
|
|
|
RMS Cohort: Percentage van deelnemers die NEDA3 hebben tijdens een periode van 24 weken
Tijdsspanne: Tot week 24
|
Tot week 24
|
|
|
RMS Cohort: Totaal aantal T1 Gadolinium (Gd)-versterkende laesies zoals gedetecteerd door Magnetische Resonantie Imaging (MRI) van de hersenen
Tijdsspanne: Tot week 48
|
Tot week 48
|
|
|
RMS Cohort: Totaal Aantal Nieuwe of Vergrote T2 Hyperintense Laesies zoals Gedetecteerd door Hersen-MRI
Tijdsspanne: Tot week 48
|
Tot week 48
|
|
|
RMS en PPMS Cohort: Verandering van de uitgangswaarde tot week 48 in de concentratie van serum neurofilament lichte keten (Nfl)
Tijdsspanne: Baseline tot week 48
|
Baseline tot week 48
|
|
|
RMS- en PPMS-cohorten: serumconcentratie van ocrelizumab
Tijdsspanne: Tot week 48
|
Tot week 48
|
|
|
RMS Cohort: B-celniveaus in het bloed
Tijdsspanne: Tot week 48
|
Tot week 48
|
|
|
RMS Cohort: Percentage van deelnemers die CD19+ B-celgehalten van <10 cellen/µL bereiken bij Week 48
Tijdsspanne: Na 48 weken
|
Na 48 weken
|
|
|
PPMS Cohort: Totaal aantal T1 Gd-versterkende laesies zoals gedetecteerd door hersen-MRI op week 24 en week 48
Tijdsspanne: Week 24 en Week 48
|
Week 24 en Week 48
|
|
|
PPMS Cohort: Totaal aantal nieuwe of vergrote T2-hyperintense laesies zoals gedetecteerd door hersen-MRI in week 24 en week 48
Tijdsspanne: Week 24 en Week 48
|
Week 24 en Week 48
|
|
|
RMS en PPMS Cohorten: Aantal deelnemers met bijwerkingen (AE's)
Tijdsspanne: Tot ongeveer 1,8 jaar
|
Tot ongeveer 1,8 jaar
|
|
|
RMS- en PPMS-cohorts: Verandering ten opzichte van de uitgangswaarde in T-celniveau
Tijdsspanne: Tot ongeveer 1,8 jaar
|
Tot ongeveer 1,8 jaar
|
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Expanded Disability Status Scale (EDSS)
Tijdsspanne: Baseline up to Week 48
|
EDSS is a scale for assessing neurologic impairment in participants with multiple sclerosis (MS). EDSS is based on a standard neurological examination, incorporating functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral [or mental]) that are rated and then scored as a functional systems scores (FSS), and ambulation, which is scored as ambulation score. Each FSS is an ordinal clinical rating scale ranging from 0 to 5 or 6 and an ambulation score that is rated from 0 to 16. These ratings are then used in conjunction with observations, as well as information, concerning ambulation and use of assistive devices to determine the total EDSS score. Values are from 0 points (normal neurological examination) up to 10 points (death), increasing in increments of 0.5 points. Higher scores represent increased disability. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Timed 25-Foot Walk Test (T25FWT)
Tijdsspanne: Baseline up to Week 48
|
The T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant is directed to start at one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly and safely as possible and immediately walk back the same distance. Score for the T25FWT is the average of the two completed trials. The time taken to complete the test is measured in seconds. The longer it takes to walk, higher the score, which indicates deterioration and greater impairment. Lower times indicate better performance and greater mobility. A 20% change from baseline of the averaged T25FWT is typically considered clinically meaningful. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in 9-Hole Peg Test (9-HPT)
Tijdsspanne: Baseline up to Week 48
|
The 9-HPT is a performance measure used to assess upper extremity (arm and hand) function. Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. More time indicates higher raw scores, which indicates deterioration. A 20% change from baseline is typically considered clinically meaningful. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline in EuroQoL 5-Dimension Questionnaire (5-Level Version; EQ-5D-5L) Index Score at Week 48
Tijdsspanne: Baseline, Week 48
|
The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. |
Baseline, Week 48
|
|
RMS and PPMS Cohorts: Percentage of Participants With Suicidal Ideation or Behaviour, as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Tijdsspanne: Up to approximately 1.8 years
|
C-SSRS is an assessment tool used to assess lifetime suicidality of participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, and attempts with actual/potential lethality. Categories have binary responses (yes/no) and include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher indicate suicidal ideation or behavior. |
Up to approximately 1.8 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Clinical Trials, Hoffmann-La Roche
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het zenuwstelsel
- Pathologische processen
- Chronische ziekte
- Ziekte attributen
- Auto-immuunziekten
- Ziekten van het immuunsysteem
- Demyeliniserende auto-immuunziekten, CZS
- Auto-immuunziekten van het zenuwstelsel
- Demyeliniserende ziekten
- Pathologische aandoeningen, tekenen en symptomen
- Multiple sclerose
- Multiple sclerose, chronisch progressief
- ocrelizumab
Andere studie-ID-nummers
- YN44938
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .